A Phase 2a, Open-label, Pilot Study to Evaluate Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of MYK-224 in Participants With Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction
CLINICAL TRIAL WITH MEDICINES
Clinical trial information
- Promoter: MYOKARDIA, INC.
- Phase: II
- Execution start: 08/12/2022
- End of execution: 01/08/2023
- IP: JUAN JIMENEZ JAIMEZ